While studies published more than a decade ago established that PD-L1 promotes cancer immune escape [82, 83] and that blocking PD-L1 can improve the anti-tumor efficacy of anti-tumor responses [84–86], whether PD-L1 expression by solid tumors negatively affects patient prognosis remains unclear. This evidence concerns the gene CD274 and cancer.